Fig. 3: Mutations attributed to spontaneous deamination of methylcytosine as biomarker for HRD detection. | Communications Biology

Fig. 3: Mutations attributed to spontaneous deamination of methylcytosine as biomarker for HRD detection.

From: CG>TG mutation frequency as negative predictor of homologous recombination deficiency in ovarian and breast cancer

Fig. 3: Mutations attributed to spontaneous deamination of methylcytosine as biomarker for HRD detection.

The fraction of C > T transitions at CpG sites relative to all SBSs (fdeam) was investigated for the ability to separate between HR-deficient and -proficient tumors. A Correlation analysis of fdeam and HRDsum in ovarian cancer (TCGA-OV). B Same as (A), but in the in-house cohort (HD-OV). C Separation between HR-deficient and -proficient ovarian carcinomas (TCGA-OV). D Same as (C), but for the in-house cohort (HD-OV). E Separation between HR-deficient and –proficient breast cancers (TCGA-BRCA). F Separation between HR-deficient and –proficient pan-cancer excluding ovarian and breast cancer. TCGA-PANCAN* = all entities included in the TCGA except BRCA and OV.

Back to article page